Table 1.

Baseline characteristics of all of the studies included in the meta-analysis.

Study	Country	Type of malignancy	Study design	No. of patients	Mean age (years)	Test method	Cutoff value	No. of cases with PINX1 expression		Outcome measures	Median follow- up time (months)	NOS score
								Low	High
Bai 2015 [20]	China	Glioma	R	583	47	IHC + TMA	Staining index∗ ≤4	217	366	OSMA   DSSMA	60	7
Cai 2010 [11]	China	Ovarian carcinoma	R	157	51	IHC + TMA	Stained cells <60.0%	53	104	OSUA	NA	6
Deng 2015 [12]	China	Colorectal cancer	R	83	58	IHC	Staining index∗ ≤4	36	47	OSUA   DFSUA	NA	6
Feng 2017 [14]	China	Breast cancer	R	59	50	IHC + TMA	Stained cells <62.5%	35	24	NA	NA	6
Li 2015 [10]	China	Renal cell carcinoma	R	353	NA	IHC + TMA	Staining index∗ ≤3	203	150	OSMA   DFSMA	60	5
Liu 2013 [16]	China	Bladder urothelial carcinoma	R	187	60	IHC + TMA	Stained cells <50.0%	83	104	OSUA   RFSUA	92	7
Ma 2008 [23]	China	Gastric cancer	R	90	NA	IHC	Staining index∗ ≤3	38	52	NA	NA	5
Qian 1 2013 [21]	China	Esophageal cancer	R	98	55	IHC	Stained cells <50.0%	40	58	DSSMA	NA	7
Qian 2 2013 [21]	China	Esophageal cancer	R	59	55	IHC	Stained cells <50.0%	26	33	DSSMA	NA	7
Qian 2016 [13]	China	Colorectal cancer	R	86	55	IHC	Stained cells <50.0%	52	34	OSMA   DFSMA	NA	7
Rong Shi 2014 [17]	China	Prostate cancer	R	40	67	IHC + TMA	Stained cells <60.0%	27	13	NA	NA	5
Meilin Shi 2015 [15]	China	Breast cancer	R	405	NA	IHC + TMA	Staining index∗ ≤3	212	193	OSMA   DSSMA	60	7
Tian 2014 [22]	China	Cervical carcinoma	R	122	46	IHC	Stained cells <50.0%	53	69	OSUA	NA	6
Tian 1 2017 [18]	China	Non-small cell lung cancer	R	93	56	IHC	Stained cells <65.0%	56	37	OSUA	NA	6
Tian 2 2017 [18]	China	Non-small cell lung cancer	R	51	56	IHC	Stained cells <65.0%	27	24	OSUA	NA	6
Wang 2017 [19]	China	Non-small cell lung cancer	R	158	61	IHC	Stained cells <50.0%	117	41	OSUA   DFSUA	NA	7

 ^∗Staining index = staining intensity × proportion of immune-positive cells.

DFS, disease-free survival; DSS, disease-specific survival; IHC, immunohistochemistry; MA, multivariate analysis; NA, not available; No., number; NOS, Newcastle-Ottawa Quality Assessment Scale; OS, overall survival; R, retrospective; RFS, recurrence-free survival; TMA, tissue microarray; UA, univariate analysis.